135 related articles for article (PubMed ID: 37024056)
21. A competing risk analysis of the patterns and risk factors of recurrence in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy.
Tonneau M; Richard C; Routy B; Campeau MP; Vu T; Filion E; Roberge D; Mathieu D; Doucet R; Beliveau-Nadeau D; Bahig H
Radiother Oncol; 2023 Aug; 185():109697. PubMed ID: 37169303
[TBL] [Abstract][Full Text] [Related]
22. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer.
Chang JY; Liu H; Balter P; Komaki R; Liao Z; Welsh J; Mehran RJ; Roth JA; Swisher SG
Radiat Oncol; 2012 Sep; 7():152. PubMed ID: 22963661
[TBL] [Abstract][Full Text] [Related]
23. Role of stereotactic body radiotherapy for early-stage non-small-cell lung cancer in patients borderline for surgery due to impaired pulmonary function.
Tomita N; Okuda K; Kita N; Niwa M; Hashimoto S; Murai T; Ishikura S; Nakanishi R; Shibamoto Y
Asia Pac J Clin Oncol; 2022 Dec; 18(6):634-641. PubMed ID: 35098662
[TBL] [Abstract][Full Text] [Related]
24. Stereotactic body radiotherapy versus surgery for early-stage non-small cell lung cancer: an updated meta-analysis involving 29,511 patients included in comparative studies.
Viani GA; Gouveia AG; Yan M; Matsuura FK; Moraes FY
J Bras Pneumol; 2022; 48(3):e20210390. PubMed ID: 35508065
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
26. Comparison of Long-term Survival of Patients With Early-Stage Non-Small Cell Lung Cancer After Surgery vs Stereotactic Body Radiotherapy.
Chi A; Fang W; Sun Y; Wen S
JAMA Netw Open; 2019 Nov; 2(11):e1915724. PubMed ID: 31747032
[TBL] [Abstract][Full Text] [Related]
27. Stereotactic ablative radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of local control, survival and toxicity outcomes.
Shanker MD; Moodaley P; Soon W; Liu HY; Lee YY; Pryor DI
J Med Imaging Radiat Oncol; 2021 Dec; 65(7):956-968. PubMed ID: 34396706
[TBL] [Abstract][Full Text] [Related]
28. Lobar Gross Endobronchial Disease Predicts for Overall Survival and Grade 5 Pulmonary Toxicity in Medically Inoperable Early Stage Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
Aghdam N; Lischalk JW; Marin MP; Hall C; O'Connor T; Campbell L; Suy S; Collins SP; Margolis M; Krochmal R; Anderson E; Collins BT
Front Oncol; 2021; 11():728519. PubMed ID: 34912703
[TBL] [Abstract][Full Text] [Related]
29. Stereotactic Body Radiation Therapy With a High Maximum Dose Improves Local Control, Cancer-Specific Death, and Overall Survival in Peripheral Early-Stage Non-Small Cell Lung Cancer.
Tateishi Y; Takeda A; Horita N; Tsurugai Y; Eriguchi T; Kibe Y; Sanuki N; Kaneko T
Int J Radiat Oncol Biol Phys; 2021 Sep; 111(1):143-151. PubMed ID: 33891980
[TBL] [Abstract][Full Text] [Related]
30. Changes in treatment patterns and survival in elderly patients with stage I non-small-cell lung cancer with the introduction of stereotactic body radiotherapy and video-assisted thoracic surgery.
Detillon DDEMA; Driessen EJM; Aarts MJ; Janssen-Heijnen MLG; van Eijck CHJ; Veen EJ
Eur J Cancer; 2018 Sep; 101():30-37. PubMed ID: 30014972
[TBL] [Abstract][Full Text] [Related]
31. Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis.
Chi A; Chen H; Wen S; Yan H; Liao Z
Radiother Oncol; 2017 Jun; 123(3):346-354. PubMed ID: 28545956
[TBL] [Abstract][Full Text] [Related]
32. Local control and survival after stereotactic body radiation therapy of early-stage lung cancer patients in Slovenia.
Stanic K; But-Hadzic J; Zagar J; Vrankar M
Radiol Oncol; 2023 Sep; 57(3):389-396. PubMed ID: 37494591
[TBL] [Abstract][Full Text] [Related]
33. Stereotactic ablative radiotherapy in T1-2N0M0 small cell lung cancer: A systematic review and meta-analysis.
Safavi AH; Mak DY; Boldt RG; Chen H; Louie AV
Lung Cancer; 2021 Oct; 160():179-186. PubMed ID: 34330566
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of stereotactic body radiotherapy versus lobectomy for stage I non-small cell lung cancer: a propensity score matching analysis.
Lin Q; Sun X; Zhou N; Wang Z; Xu Y; Wang Y
BMC Pulm Med; 2019 May; 19(1):98. PubMed ID: 31118007
[TBL] [Abstract][Full Text] [Related]
35. Maximum standardized uptake value on FDG-PET is a strong predictor of overall and disease-free survival for non-small-cell lung cancer patients after stereotactic body radiotherapy.
Takeda A; Sanuki N; Fujii H; Yokosuka N; Nishimura S; Aoki Y; Oku Y; Ozawa Y; Kunieda E
J Thorac Oncol; 2014 Jan; 9(1):65-73. PubMed ID: 24346094
[TBL] [Abstract][Full Text] [Related]
36. Medically inoperable peripheral lung cancer treated with stereotactic body radiation therapy.
Kelley KD; Benninghoff DL; Stein JS; Li JZ; Byrnes RT; Potters L; Knisely JP; Zinkin HD
Radiat Oncol; 2015 May; 10():120. PubMed ID: 26018408
[TBL] [Abstract][Full Text] [Related]
37. Stereotactic body radiotherapy for synchronous early stage non-small cell lung cancer.
Steber CR; Hughes RT; Soike MH; Helis CA; Nieto K; Jacobson T; Nagatsuka M; McGinnis HS; Leyrer CM; Farris MK
Acta Oncol; 2021 May; 60(5):605-612. PubMed ID: 33645424
[TBL] [Abstract][Full Text] [Related]
38. Relationship between the consolidation to maximum tumor diameter ratio and outcomes following stereotactic body radiotherapy for stage I non-small-cell lung cancer.
Tsurugai Y; Kozuka T; Ishizuka N; Oguchi M
Lung Cancer; 2016 Feb; 92():47-52. PubMed ID: 26775596
[TBL] [Abstract][Full Text] [Related]
39. Video-assisted thoracoscopic lobectomy versus stereotactic radiotherapy for stage I lung cancer.
Hamaji M; Chen F; Matsuo Y; Kawaguchi A; Morita S; Ueki N; Sonobe M; Nagata Y; Hiraoka M; Date H
Ann Thorac Surg; 2015 Apr; 99(4):1122-9. PubMed ID: 25661580
[TBL] [Abstract][Full Text] [Related]
40. Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy.
Horne ZD; Clump DA; Vargo JA; Shah S; Beriwal S; Burton SA; Quinn AE; Schuchert MJ; Landreneau RJ; Christie NA; Luketich JD; Heron DE
Radiat Oncol; 2014 Jan; 9():41. PubMed ID: 24479954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
